Pregabalin Market

The Pregabalin market is projected to grow at a CAGR of 7.5% from 2025 to 2035, driven by increasing prevalence of neuropathic pain, epilepsy, generalized anxiety disorder (GAD), and fibromyalgia, alongside growing awareness of its efficacy and safety profile. Pregabalin is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA), though it does not bind directly to GABA receptors. Instead, it binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and thereby decreasing the release of excitatory neurotransmitters. This action helps modulate neuronal excitability and alleviate symptoms of nerve pain and seizures.

Pregabalin is widely prescribed for managing neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury. It is also used as an adjunctive therapy for partial-onset seizures and for treating generalized anxiety disorder in several countries. Its favorable oral bioavailability, predictable pharmacokinetics, and well-tolerated side effect profile contribute to its strong market demand.

North America leads the Pregabalin market due to high prevalence of neuropathic pain conditions, established healthcare infrastructure, and widespread clinical acceptance. Europe follows with steady growth supported by reimbursement frameworks and increasing off-label use. The Asia-Pacific region is expected to witness the fastest growth driven by rising incidence of neurological disorders, expanding healthcare access, and increasing pharmaceutical manufacturing capacity in countries like China and India. Latin America and the Middle East & Africa are showing gradual market expansion with improving diagnosis rates and healthcare infrastructure.